Wave Life Sciences Q1 net loss $31.6M; cash $180.9M; pipeline milestones on track

Wave Life Sciences Ltd.

2024-Q1 EPS reported -$0.24 revenue$12,538,000

Q1 revenue $12.5M (vs $12.9M YoY); net loss $31.6M (vs $27.4M). Cash $180.9M; plus $12M from GSK milestone in April.
RestorAATion-2 for AATD underway; proof-of-mechanism data expected in 2024.
INHBE obesity program targets 1Q 2025 trial start; preclinical weight loss similar to semaglutide with fat loss, no muscle loss.
FORWARD-53 DMD 24-week dystrophin data expected 3Q 2024; SELECT-HD multi-dose data expected 2Q 2024.
Appointed Dr. Erik Ingelsson as CSO to drive genetic target discovery; GSK advanced two programs triggering $12M payment.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Wave Life Sciences Ltd. reported financial results for the quarter ended March 31, 2024.

Period: the quarter ended March 31, 2024
Result: reported results

Exact text from the filing

On May 9, 2024, Wave Life Sciences Ltd. (the “Company”) announced its financial results for the quarter ended March 31, 2024.

View on SEC.gov

1447 earnings releases filed in the last 30 days. Browse all earnings releases →

Wave Life Sciences Ltd. filing history →

Source: SEC EDGAR

accession 0001193125-24-134769

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.